Single- and Dual-Hormone Artificial Pancreas for Overnight Glucose Control in Type 1 Diabetes
Одногормональная и двухгормональная искусственная поджелудочная железа для контроля уровня глюкозы в ночное время у пациентов с сахарным диабетом 1 типа
2015-11-02
SCID: 54.1/n7wwqhk6
Discuss with AI
continuous glucose monitoringdual-hormone artificial pancreasovernight glucose controlsingle-hormone artificial pancreastype 1 diabetes
Figures from the paper
Abstract (AI)
CONTEXT: The added benefit of glucagon in artificial pancreas systems for overnight glucose control in type 1 diabetes has not been fully explored. OBJECTIVE: The objective of the study was to compare the efficacy of dual-hormone (insulin and glucagon) artificial pancreas, single-hormone (insulin alone) artificial pancreas, and conventional insulin pump therapy. DESIGN: This study was a three-center, three-arm, open-label, randomized, crossover controlled trial involving three interventions, each applied over a night after a high carbohydrate/high fat meal and a second after exercise to mimic real-life glycemic excursions. SETTING: The study was conducted in a home setting. PATIENTS: Twenty-eight type 1 diabetes participants (21 adults and seven adolescents) participated in the study. INTERVENTIONS: Dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional pump therapy was activated from 9:00 PM to 7:00 AM. MAIN OUTCOME: The main outcome was a proportion of time in target (4-8 mmol/L) by continuous glucose monitoring from 11:00 PM to 7:00 AM. Analysis was by intention to treat. RESULTS: The median (interquartile range) percentage of time-in-target glucose range was 47% (36%-71%) for conventional therapy, higher on both single-hormone (76% [65%-91%], P < .001) and dual-hormone artificial pancreas (81 [68%-93%], P < .001). The median (interquartile range) time spent below 4 mmol/L was 14% (4%-28%) for conventional therapy, lower on both single-hormone (5% [0%-13%], P = .004) and dual-hormone artificial pancreas (1% [0%-8%], P < .001). There were 14 hypoglycemic events on conventional therapy compared with six incidences on the single-hormone artificial pancreas (P = .059) and three incidences on the dual-hormone artificial pancreas (P = .017). None of these outcomes differed significantly between single- and dual-hormone configurations. CONCLUSIONS: Single- and dual-hormone artificial pancreas systems both provided better glucose control than conventional therapy. Although the dual-hormone configuration did not increase overnight time-in-target glucose levels, an effect on lowering hypoglycemia risk cannot be ruled out.
Key Findings
1
Both single-hormone and dual-hormone artificial pancreas systems significantly increased overnight time in the target glucose range compared with conventional pump therapy.
2
Hypoglycemic events were significantly fewer with the dual-hormone system than conventional therapy, while the reduction with single-hormone therapy was not statistically significant.
3
Median time in range increased from 47% with conventional therapy to 76% with single-hormone and 81% with dual-hormone artificial pancreas systems.
4
No measured glucose-control or hypoglycemia outcome differed significantly between single- and dual-hormone artificial pancreas configurations, indicating no demonstrated added overnight benefit from glucagon.
5
Time spent below 4 mmol/L decreased from 14% with conventional therapy to 5% with single-hormone and 1% with dual-hormone systems.
Research Object
Artificial pancreas systems for overnight glucose control in people with type 1 diabetes
Research Subject
The comparative efficacy of single-hormone (insulin-only) and dual-hormone (insulin-and-glucagon) artificial pancreas systems versus conventional insulin pump therapy in maintaining target glucose levels and preventing hypoglycemia overnight
Publication Details
Publication Date
2015-11-02
Journal
Publisher
ISSN
Cited by
94
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai4
Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes2010
Nocturnal Glucose Control with an Artificial Pancreas at a Diabetes Camp2013
Effect of Sensor-Augmented Insulin Pump Therapy and Automated Insulin Suspension vs Standard Insulin Pump Therapy on Hypoglycemia in Patients With Type 1 Diabetes: A Randomized Clinical Trial2013
Night glucose control with MD-Logic artificial pancreas in home setting: a single blind, randomized crossover trial-interim analysis2013